4/7/2024

Penicillin G Benzathine / Penicillin G Procaine

Products Affected - Description

- Bicillin C-R intramuscular suspension for injection, Pfizer, 1,200,000 units (600,000 units penicillin G benzathine/600,000 units penicillin G procaine), 2 mL prefilled syringe, 10 count, NDC 60793-0600-10
- Bicillin C-R intramuscular suspension for injection, Pfizer, 1,200,000 units (600,000 units penicillin G benzathine/600,000 units penicillin G procaine), 2 mL pediatric prefilled syringe, 10 count, NDC 60793-0601-10
- Bicillin C-R 900/300 intramuscular suspension for injection, Pfizer, 1,200,000 units (900,000 units penicillin G benzathine/300,000 units penicillin G procaine), 2 mL pediatric prefilled syringe, 10 count, NDC 60793-0602-10

Reason for the Shortage

- Pfizer has Bicillin-CR on shortage due to increased demand and manufacturing delays. Pfizer is allocating resources towards manufacturing Bicillin-LA due to increased syphilis infection rates. A Dear Healthcare Professional Letter can be found at: https://www.fda.gov/media/169427/download.

Available Products

- There is insufficient supply for usual ordering

Estimated Resupply Dates

- Pfizer has Bicillin-CR 1,200,000 units adult 2 mL syringes and 1,200,000 units pediatric 2 mL syringes on back order and the company estimates a release date of June 2025. The Bicillin-CR (900/300) 2 mL syringes are on back order and the company estimates a release date of June 2025.

Updated

Updated April 7, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created March 31, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.